JP7229173B2 - 組み換えウイルスを産生するための方法 - Google Patents

組み換えウイルスを産生するための方法 Download PDF

Info

Publication number
JP7229173B2
JP7229173B2 JP2019555574A JP2019555574A JP7229173B2 JP 7229173 B2 JP7229173 B2 JP 7229173B2 JP 2019555574 A JP2019555574 A JP 2019555574A JP 2019555574 A JP2019555574 A JP 2019555574A JP 7229173 B2 JP7229173 B2 JP 7229173B2
Authority
JP
Japan
Prior art keywords
deletion
seq
recombinant
oncolytic adenovirus
recombinant oncolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516277A (ja
JP2020516277A5 (enExample
Inventor
リード，トニー，アール．
オロンスキー，ブライアン，ティー．
ラーソン，クリストファー
Original Assignee
エピセントアールエックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピセントアールエックス，インコーポレイテッド filed Critical エピセントアールエックス，インコーポレイテッド
Publication of JP2020516277A publication Critical patent/JP2020516277A/ja
Publication of JP2020516277A5 publication Critical patent/JP2020516277A5/ja
Priority to JP2023020698A priority Critical patent/JP2023053298A/ja
Application granted granted Critical
Publication of JP7229173B2 publication Critical patent/JP7229173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019555574A 2017-04-10 2018-04-10 組み換えウイルスを産生するための方法 Active JP7229173B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020698A JP2023053298A (ja) 2017-04-10 2023-02-14 組み換えウイルスを産生するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483837P 2017-04-10 2017-04-10
US62/483,837 2017-04-10
PCT/US2018/026977 WO2018191313A1 (en) 2017-04-10 2018-04-10 Method for producing recombinant virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020698A Division JP2023053298A (ja) 2017-04-10 2023-02-14 組み換えウイルスを産生するための方法

Publications (3)

Publication Number Publication Date
JP2020516277A JP2020516277A (ja) 2020-06-11
JP2020516277A5 JP2020516277A5 (enExample) 2021-05-20
JP7229173B2 true JP7229173B2 (ja) 2023-02-27

Family

ID=63792776

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555574A Active JP7229173B2 (ja) 2017-04-10 2018-04-10 組み換えウイルスを産生するための方法
JP2023020698A Withdrawn JP2023053298A (ja) 2017-04-10 2023-02-14 組み換えウイルスを産生するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020698A Withdrawn JP2023053298A (ja) 2017-04-10 2023-02-14 組み換えウイルスを産生するための方法

Country Status (8)

Country Link
US (2) US11999973B2 (enExample)
EP (1) EP3610003A4 (enExample)
JP (2) JP7229173B2 (enExample)
KR (2) KR20240032169A (enExample)
CN (1) CN111133102B (enExample)
AU (1) AU2018253088B2 (enExample)
CA (1) CA3059605A1 (enExample)
WO (1) WO2018191313A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023053298A (ja) * 2017-04-10 2023-04-12 エピセントアールエックス，インコーポレイテッド 組み換えウイルスを産生するための方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN111793595A (zh) * 2020-07-23 2020-10-20 上海奥浦迈生物科技有限公司 一种hek293细胞无血清培养基
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515172A (ja) 2003-12-23 2007-06-14 シェーリング　コーポレイション 無血清培地懸濁培養において安定なａ５４９細胞株を生成するための方法
WO2010101921A2 (en) 2009-03-02 2010-09-10 The Regents Of The University Of California Tumor-selective e1a and e1b mutants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2003039459A2 (en) 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
JP4301558B2 (ja) * 2003-12-26 2009-07-22 日東電工株式会社 偏光板用接着剤、偏光板、その製造方法、光学フィルムおよび画像表示装置
US20190352669A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515172A (ja) 2003-12-23 2007-06-14 シェーリング　コーポレイション 無血清培地懸濁培養において安定なａ５４９細胞株を生成するための方法
WO2010101921A2 (en) 2009-03-02 2010-09-10 The Regents Of The University Of California Tumor-selective e1a and e1b mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILBERT R. et al.，Journal of Virological Methods，2014年，208，p.177-188
HEDJRAN F. et al.，Cancer Gene Therapy，2011年，18，p.717-723
LONGLEY R. Jr. et al.，Cytotechnology，2005年，49，p.161-171

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023053298A (ja) * 2017-04-10 2023-04-12 エピセントアールエックス，インコーポレイテッド 組み換えウイルスを産生するための方法

Also Published As

Publication number Publication date
CN111133102B (zh) 2024-08-16
US12291726B2 (en) 2025-05-06
WO2018191313A1 (en) 2018-10-18
KR20200004313A (ko) 2020-01-13
JP2023053298A (ja) 2023-04-12
US20240294883A1 (en) 2024-09-05
JP2020516277A (ja) 2020-06-11
AU2018253088B2 (en) 2024-09-19
EP3610003A4 (en) 2021-01-06
US20200032223A1 (en) 2020-01-30
EP3610003A1 (en) 2020-02-19
KR20240032169A (ko) 2024-03-08
AU2018253088A1 (en) 2019-11-28
CN111133102A (zh) 2020-05-08
KR102643016B1 (ko) 2024-02-29
US11999973B2 (en) 2024-06-04
CA3059605A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7229173B2 (ja) 組み換えウイルスを産生するための方法
JP7301748B2 (ja) 複数トランスジーン組み換えアデノウイルス
JP7242534B2 (ja) 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体
US20190352616A1 (en) Multiple transgene recombinant adenovirus
JP7245175B2 (ja) 抗脈管形成アデノウイルス
JP2023113963A (ja) 非組み込みウイルス送達システムおよびその使用の方法
US20250388930A1 (en) Tumor selective tata-box and caat-box mutants
HK40018033A (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
HK40018033B (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230214

R150 Certificate of patent or registration of utility model

Ref document number: 7229173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150